程序性死亡受体1和程序性死亡受体配体1在非小细胞肺癌组织中的表达情况及临床意义

目的探讨程序性死亡受体1(PD-1)和程序性死亡受体配体1(PD-L1)在非小细胞肺癌(NSCLC)组织中的表达情况及临床意义。方法选择150例NSCLC患者的NSCLC组织及其癌旁组织,采用实时荧光定量聚合酶链反应(PCR)检测两种组织中PD-1 mRNA和PD-L1 mRNA的相对表达量。采用免疫组织化学染色法检测NSCLC组织中PD-1和PD-L1的表达情况,分析PD-1和PD-L1表达情况与患者临床特征的关系。采用流式细胞术检测NSCLC组织和癌旁组织中CD4^+-PD-1、CD8^+-PD-1、CD14^+-PD-L1、CD68^+-PD-L1的表达水平。结果NSCLC组织中PD-1 mRNA和PD-L1 mRNA的相对表达量分别为(5.03±1.92)和(4.95±1.09),分别高于癌旁组织的(1.72±0.81)和(1.25±0.24),差异均有统计学意义(P﹤0.05)。TNM分期为Ⅲ~Ⅳ期、低分化、有淋巴结转移、有远处转移的NSCLC患者NSCLC组织中PD-1和PD-L1的高表达率均明显高于TNM分期为Ⅰ~Ⅱ期、高+中分化、无淋巴结转移、无远处转移的患者,差异均有统计学意义(P﹤0.01)。NSCLC组织中CD4^+-PD-1、CD8^+-PD-1、CD14^+-PD-L1、CD68^+-PD-L1的表达水平均明显高于癌旁组织,差异均有统计学意义(P﹤0.01)。结论PD-1和PD-L1在NSCLC组织中高表达,可能成为一种新的生物标志物,PD-1/PD-L1信号通路可能参与了NSCLC的免疫逃逸过程,对其逃逸机制进行研究可以为NSCLC患者的临床治疗提供新靶点。

Expression of programmed cell death 1 and programmed cell death 1 ligand 1 in non-small cell lung cancer and their clinical significance

Objective To investigate the expression of programmed cell death 1(PD-1)and programed cell death 1 ligand 1(PD-L1)in non-small cell lung cancer(NSCLC)and their clinical significance.Method The cancer tissues and surrounding tissues from 150 cases with NSCLC were analyzed.Quantitative real-time polymerase chain reaction(PCR)was used to detect the expression of PD-1 mRNA and PD-L1 mRNA in NSCLC tissues and surrounding tissues.Immunohistochemical assay was used to detect the expression of PD-1 and PD-L1 in NSCLC tissues,so as to determine their relationship with patients’clinical characteristics.Flow cytometry was applied to examine the expression of CD4^+-PD-1,CD8^+-PD-1,CD14^+-PD-L1,CD68^+-PD-L1 in NSCLC tissues and adjacent tissues.Result The relative expression of PD-1 mRNA and PD-L1 mRNA in NSCLC tissues were(5.03±1.92)and(4.95±1.09),which were significantly higher than the(1.72±0.81)and(1.25±0.24)in surrounding tissues(P<0.05).Significantly higher expression rates of PD-1 and PDL1 were observed in TNM stage III-IV,poor differentiation,positive lymph node metastasis and presence of distant metastasis compared to TNM stage I-II,high or moderate differentiation,negative lymph node metastasis,and absence of distant metastasis in NSCLC tissues from patients with NSCLC,and the differences were of statistical significance(P<0.01).In NSCLC tissues,the expression of CD4^+-PD-1,CD8^+-PD-1,CD14^+-PD-L1,CD68^+-PD-L1 were significantly higher than those in surrounding tissues(P<0.01).Conclusion The high expression of PD-1 and PD-L1 in NSCLC indicates the potential to become a new biomarker,and PD-1/PD-L1 signaling pathway may be involved in the immune escape process of NSCLC,and the study into its escape mechanism may reveal a new target for the clinical treatment of NSCLC patients.